Icure Pharmaceutical Incorporation Stock: price and insider trades · South Korea

This page follows insider dealings at Icure Pharmaceutical Incorporation as filed with DART (FSS), a company from the Health Care sector. From 3 November 2025 to 3 November 2026, the disclosure feed for Icure Pharmaceutical Incorporation logged 8 filings by 5 insiders.

Purchases and sales both appear in the filings: 2 purchases (2 insiders) and 1 sale (1 insider). The totals do not cover 3 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 board member.

With 8 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Our records for Icure Pharmaceutical Incorporation go back to 2021, with 6 purchases and 4 sales on the open market in total.

The latest purchase dates back some time: it was published 40 days ago, on 30 September 2026.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and UCB. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.